Skip to main content

25 July 2022

Biomedical Engineering spinout Hypervision Surgical graduates from prestigious programme

Only 1 of 8 companies graduated from the programme

Michael E

Spinout from King’s School of Biomedical Engineering & Imaging Sciences Hypervision Surgical has graduated from the 2021-2022 Health stream of the Creative Destruction Lab (CDL) programme as 1 of only 8 companies. It was also selected as the single company to represent CDL-Oxford in the CDL Super Session on 23 June 2022.

Only by successfully passing each session of the programme can a company continues to receive dedicated support from CDL’s world-class network of exited entrepreneurs, angel investors, and partners from leading venture capital firms.

CDL’s programme consists of a highly competitive process where participating ventures are assessed against their performance on ambitious objectives set by the CDL community every eight weeks.

CDL reviews a few hundred companies per year and admits 20 companies. Hypervision Surgical is among 8 ventures in the latest cohort to graduate.

Following this 9-month programme, Hypervision Surgical had the unique opportunity to learn from a wealth of experience of CDL mentors and its community to deliver on ambitious milestones that are critical towards bringing their high-potential technology for improved surgical care to market.

Creative Destruction Lab (CDL), at the University of Oxford’s Saïd Business School, is a non-profit organisation that delivers an objectives-based programme for massively scalable, seed-stage, science- and technology-based companies.

On behalf of Hypervision Surgical, I am incredibly grateful to our CDL mentors and the wider MedTech community for their support over the past year. Thanks to the close mentorship of highly experienced entrepreneurs, Hypervision Surgical has made vital progress toward bringing its technology to market for patient benefit.

Dr Michael Ebner, CEO and co-founder, Hypervision Surgical

Translating research results into improved patient benefits is a core mission of our work at King’s College London, School of Biomedical Engineering & Imaging Sciences. Spinning out Hypervision Surgical is of strategic importance to achieve such impact, and yet, the road to commercial success is known to be challenging in MedTech. I am delighted to see Hypervision Surgical graduating from the Creative Destruction Lab and being featured at its Super Session. It highlights King’s successful commitment to MedTech entrepreneurship.

Professor Tom Vercauteren, Professor at King’s College London, CSO and co-founder at Hypervision Surgical

Hypervision Surgical was formed as a spin-out company from King’s College London to convert a novel imaging system initially developed at BMEIS into a commercial medical device.  

In this story

Michael Ebner

Research Associate

Tom  Vercauteren

Professor of Interventional Image Computing